September 21st 2021, 1:00pm
An updated report shows that the long-term cost of treating the health effects of polycystic ovary syndrome (PCOS)—$4.3 billion—is even higher than $3.7 billion it takes to diagnose and treat immediate issues that present for women who are of reproductive age.
September 19th 2021, 12:15am
A systematic review that aimed to find out more about how growth hormone deficiency (GHD) affects children's oral and dental development found that knowledge gaps still remain.
September 18th 2021, 7:42pm
Real-world outcomes can differ from those seen in tightly-controlled clinical trials, so researchers wanted to examine the patterns of growth hormone treatment in a large cohort of children in Israel.
September 11th 2021, 10:30am
This pivotal phase 3 trial led to the recent approval of lonapegsomatropin for growth hormone deficiency.
September 8th 2021, 5:05pm
A review of cases using MRI with and without contrast agent found perfect or near-perfect agreement in most cases when evaluating patients with short stature for growth hormone deficiency.
September 3rd 2021, 1:45pm
The product, lonapegsomatropin, is a sustained-release formulation and could replace daily injections.
December 30th 2020, 3:15pm
Using advanced machine learning models, researchers in China were able to accurately predict incidence of gestational diabetes among pregnant women during their first trimester.
December 28th 2020, 3:00pm
In a cohort study of nurses, irregular and long menstrual cycles throughout life were associated with a greater risk of type 2 diabetes (T2D).
December 8th 2020, 10:15pm
Among women hospitalized with coronavirus disease 2019 (COVID-19), use of metformin—a type 2 diabetes (T2D) drug used to manage blood sugar levels—was associated with a 21.5% lower risk of death.
October 23rd 2020, 8:35pm
In her presentation, Aimee Tharaldson, PhD, senior clinical pharmacist of emerging therapeutics at Express Scripts, discussed the upcoming pipeline of specialty drug approvals and their potential impact on the market.
